Collegium Pharmaceutical, Inc. operates as a specialty biopharmaceutical company focused on developing and commercializing therapies for chronic pain management and neuropsychiatric conditions. The company's business model centers on acquiring, developing, and marketing differentiated medications that address significant unmet medical needs, particularly in the areas of responsible pain management and attention deficit hyperactivity disorder (ADHD).
Collegium's revenue is primarily generated from product sales within the United States. Its pain management portfolio includes Xtampza ER (an abuse-deterrent, extended-release formulation of oxycodone), Belbuca (a buprenorphine buccal film), the Nucynta franchise (extended and immediate-release tapentadol), and Symproic (for opioid-induced constipation). In the neuropsychiatry segment, the company's key growth driver is Jornay PM, an extended-release methylphenidate for the treatment of ADHD, which has seen significant prescription growth. The company also recently announced the planned acquisition of Azstarys, another ADHD medication, to further bolster its central nervous system (CNS) offerings.
Geographically, Collegium operates and generates its revenue entirely within the United States. The company competes in a highly regulated and competitive pharmaceutical market against other specialty drug manufacturers, such as Jazz Pharmaceuticals and various generic drug makers. Collegium differentiates itself through its proprietary DETERx microsphere technology, which provides extended-release delivery while deterring manipulation for unintended routes of abuse, positioning the company as a leader in responsible pain management solutions.
